Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.49 |
| ▸ | FABP7 | O15540 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119279 | 0.87 | FABP5 (0.48) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL2905231 | 0.82 | KMT2A (0.44) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL29413766 | 0.81 | KMT2A (0.44) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL3857048 | 0.81 | KMT2A (0.51) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL120280 | 0.81 | FABP5 (0.50) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL29403341 | 0.79 | KMT2A (0.50) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL30584150 | 0.78 | KMT2A (0.51) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL10037319 | 0.78 | KMT2A (0.51) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL119531 | 0.78 | FABP5 (0.48) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL1869833 | 0.78 | FABP5 (0.50) | FABP5FABP7KMT2AEPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060233747-A1 | Polymer-modified synthetic proteins | AMYLIN PHARMACEUTICALS, INC. (US) | 2006-10-19 | — | — | US | disclosed |
| US-7118737-B2 | Polymer-modified synthetic proteins | AMYLIN PHARMACEUTICALS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060149039-A1 | Pseudo-native chemical ligation | AMYLIN PHARMACEUTICALS, INC. (US) | 2006-07-06 | — | — | US | disclosed |
| EP-1315738-A4 | EXTENDED NATIVE CHEMICAL LIGATION | GRYPHON THERAPEUTICS INC (US) | 2006-06-07 | — | — | EP | disclosed |
| US-7030218-B2 | Pseudo native chemical ligation | GRYPHON THERAPEUTICS (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1315513-A4 | \"PSEUDO\"-NATIVE CHEMICAL LIGATION | GRYPHON THERAPEUTICS INC (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1318827-A4 | POLYMER-MODIFIED SYNTHETIC PROTEINS | GRYPHON THERAPEUTICS INC (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040138412-A1 | Extended native chemical ligation | AMYLIN PHARMACEUTICALS, INC. | 2004-07-15 | — | — | US | disclosed |
| US-20040115774-A1 | Polymer-modified synthetic proteins | AMYLIN PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20030208046-A1 | Pseudo native chemical ligation | ASTRAZENECA PHARMACEUTICALS LP | 2003-11-06 | — | — | US | disclosed |
| US-20030191291-A1 | Synthetic erythropoiesis stimulating proteins | GRYPHON THERAPEUTICS, INC. | 2003-10-09 | — | — | US | disclosed |
| EP-1318827-A1 | POLYMER-MODIFIED SYNTHETIC PROTEINS | Gryphon Therapeutics, Inc. (US) | 2003-06-18 | — | — | EP | disclosed |
| EP-1315513-A2 | \"PSEUDO\"-NATIVE CHEMICAL LIGATION | Gryphon Therapeutics, Inc. (US) | 2003-06-04 | — | — | EP | disclosed |
| EP-1315738-A1 | EXTENDED NATIVE CHEMICAL LIGATION | Gryphon Therapeutics, Inc. (US) | 2003-06-04 | — | — | EP | disclosed |
| WO-2002020034-A1 | 'PSEUDO'-NATIVE CHEMICAL LIGATION | GRYPHON THERAPEUTICS, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002020033-A1 | POLYMER-MODIFIED SYNTHETIC PROTEINS | GRYPHON THERAPEUTICS, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002020557-A1 | EXTENDED NATIVE CHEMICAL LIGATION | GRYPHON THERAPEUTICS, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138412-A1 | Extended native chemical ligation | LNPEP, GFER, QPCT | FABP5 1615/4885FABP7 2043/4885KMT2A 2059/4885 |
| US-20060233747-A1 | Polymer-modified synthetic proteins | ADM2, PTMS, NGLY1 | FABP5 324/4885FABP7 494/4885KMT2A 3991/4885 |
| US-20030208046-A1 | Pseudo native chemical ligation | PTMS, ACP1, NGLY1 | FABP5 172/4885FABP7 598/4885KMT2A 3063/4885 |
| US-20060149039-A1 | Pseudo-native chemical ligation | PTMS, QPCTL, ACP1 | FABP5 136/4885FABP7 416/4885KMT2A 2628/4885 |
| US-20030191291-A1 | Synthetic erythropoiesis stimulating proteins | EPOR, HAMP, HBG2 | FABP5 357/4885FABP7 766/4885KMT2A 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.